CLINICAL STUDY RESULTS

Bring on

The Fight to Cancer

See how BAVENCIO® (avelumab) was studied as a maintenance treatment in certain patients with advanced urothelial carcinoma (UC)

Study Design

 

  • Patients with either PD-L1-positive or negative tumors were included
  • Patients with autoimmune disease or a medical condition that required immunosuppression were not included
  •  

    *Supportive care included antibiotics, nutritional support, hydration, and pain management.

    In some cancer types, when cancer cells have high amounts of a protein called PD-L1, they can trick the immune system and avoid being attacked as harmful substances. Speak to your doctor to learn more about the role of PD-L1 in advanced UC.

    PD-L1=programmed death ligand 1.

    Common side effects seen in the clinical study

    The most common side effects of BAVENCIO as maintenance treatment in people with urothelial carcinoma (UC) whose cancer responded or stabilized after platinum-containing chemotherapy as first treatment include: feeling tired, muscle and bone pain, urinary tract infection, and rash.

    Click here to see full Important Safety Information

    BAVENCIO plus supportive care helped some patients live longer than those on supportive care alone

    CLINICAL STUDY RESULTS

    Study result

    *Half the patients lived longer than 21.4 months and the other half lived less than 21.4 months.

    Half the patients lived longer than 14.3 months and the other half lived less than 14.3 months.

    FOLLOW-UP ANALYSIS

    In a follow-up analysis that was completed on June 4, 2021:


    LIMITATIONS

    Based on the design of the study, conclusions should not be drawn from the follow-up analysis.
     

    Blue Arrow
    grey arrow callout

    *Half the patients lived longer than 23.8 months, and the other half lived less than 23.8 months.

    Half the patients lived longer than 15.0 months, and the other half lived less than 15.0 months.

    BAVENCIO can be used as a maintenance treatment, regardless of PD-L1 status.